Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27283486,area-under the time-activity curve,Lop kinetics and radiometabolites in arterial plasma were measured to calculate [(11)C]dLop area-under the time-activity curve from 10 to 30min in the brain (AUCbrain) and in plasma (AUCplasma).,Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),min,10 to 30,5092,DB00836,Loperamide
,27283486,AUCR,Baseline AUCR (0.85±0.29) was significantly enhanced in the presence of CsA (AUCR=10.8±3.6).,Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,0.85,5093,DB00836,Loperamide
,27283486,AUCR,Baseline AUCR (0.85±0.29) was significantly enhanced in the presence of CsA (AUCR=10.8±3.6).,Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,10.8,5094,DB00836,Loperamide
,27283486,AUCR,"Injection of pharmacologic dose of DPy did not enhance [(11)C]dLop brain distribution with AUCR being 1.2, 0.9 and 1.1 after administration of 0.56, 0.96 and 2mg/kg DPy doses, respectively.",Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,1.2,5095,DB00836,Loperamide
,27283486,AUCR,"Injection of pharmacologic dose of DPy did not enhance [(11)C]dLop brain distribution with AUCR being 1.2, 0.9 and 1.1 after administration of 0.56, 0.96 and 2mg/kg DPy doses, respectively.",Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,0.9,5096,DB00836,Loperamide
,27283486,AUCR,"Injection of pharmacologic dose of DPy did not enhance [(11)C]dLop brain distribution with AUCR being 1.2, 0.9 and 1.1 after administration of 0.56, 0.96 and 2mg/kg DPy doses, respectively.",Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,1.1,5097,DB00836,Loperamide
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[ng] / [ml],53.9,5277,DB00836,Loperamide
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[ng] / [ml],90.7,5278,DB00836,Loperamide
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[ng] / [ml],16.5,5279,DB00836,Loperamide
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[ng] / [ml],20.0,5280,DB00836,Loperamide
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[pg] / [ml],80.8,5281,DB00836,Loperamide
,18299336,C(max),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[pg] / [ml],101,5282,DB00836,Loperamide
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[h·ng] / [ml],263,5283,DB00836,Loperamide
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[h·ng] / [ml],435,5284,DB00836,Loperamide
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[h·ng] / [ml],54.5,5285,DB00836,Loperamide
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[h·ng] / [ml],75.7,5286,DB00836,Loperamide
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[h·pg] / [ml],467,5287,DB00836,Loperamide
,18299336,AUC(0-8),"The C(max) was 53.9 +/- 13.1 and 90.7 +/- 23.1 ng/ml for fexofenadine, 16.5 +/- 3.4 and 20.0 +/- 7.9 ng/ml for quinidine, and 80.8 +/- 9.0 and 101 +/- 15 pg/ml for loperamide, and the AUC(0-8) was 263 +/- 62 and 435 +/- 95 ng x h/ml for fexofenadine, 54.5 +/- 11.5 and 75.7 +/- 21.8 ng x h/ml for quinidine, and 467 +/- 85 and 556 +/- 91 pg x h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively.","Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18299336/),[h·pg] / [ml],556,5288,DB00836,Loperamide
,16419413,flow rate,The mobile phase consisted of 0.1% formic acid in deionized water (60%) and acetonitrile (40%) at a flow rate of 0.5 mL/min.,Tissue distribution of loperamide and N-desmethylloperamide following a fatal overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419413/),[ml] / [min],0.5,10347,DB00836,Loperamide
,16419413,Heart blood concentrations,"Heart blood concentrations for loperamide and its metabolite were 1.2 mg/L and 3.3 mg/L, respectively.",Tissue distribution of loperamide and N-desmethylloperamide following a fatal overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419413/),[mg] / [l],1.2,10348,DB00836,Loperamide
,16419413,Heart blood concentrations,"Heart blood concentrations for loperamide and its metabolite were 1.2 mg/L and 3.3 mg/L, respectively.",Tissue distribution of loperamide and N-desmethylloperamide following a fatal overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419413/),[mg] / [l],3.3,10349,DB00836,Loperamide
not exceed,16419413,peak plasma concentrations,"In contrast, reported peak plasma concentrations of loperamide after administration of recommended daily doses of 16 mg did not exceed 0.012 mg/L in controlled trials.",Tissue distribution of loperamide and N-desmethylloperamide following a fatal overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419413/),[mg] / [l],0.012,10350,DB00836,Loperamide
,10873073,MTD,"For patients with no prior AP radiation therapy, the MTD was determined to be 320 mg/m2, whereas those with prior AP radiation therapy had a MTD of 290 mg/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[mg] / [m2],320,17617,DB00836,Loperamide
,10873073,MTD,"For patients with no prior AP radiation therapy, the MTD was determined to be 320 mg/m2, whereas those with prior AP radiation therapy had a MTD of 290 mg/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[mg] / [m2],290,17618,DB00836,Loperamide
,10873073,terminal phase half-life,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),h,12.4,17619,DB00836,Loperamide
,10873073,clearance,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [h·m2],13.0,17620,DB00836,Loperamide
,10873073,clearance,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [m2],234,17621,DB00836,Loperamide
,10873073,terminal phase volume of distribution,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [h·m2],13.0,17622,DB00836,Loperamide
,10873073,steady-state volume of distribution,"Mean values of terminal phase half-life, clearance, terminal phase volume of distribution, and steady-state volume of distribution for CPT-11 were 12.4 +/- 1.8 h, 13.0 +/- 3.8 liters/h/m2, 234 +/- 83 liters/m2, and 123 +/- 38 liters/m2, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873073/),[l] / [m2],123,17623,DB00836,Loperamide
,11719726,area under the concentration-time curve,"Ritonavir caused a major pharmacokinetic interaction, increasing the area under the concentration-time curve of loperamide from 104 +/- 60 h x pmol/ml after placebo to 276 +/- 68 h.",Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719726/),[h·pM] / [ml],104,38654,DB00836,Loperamide
,11719726,area under the concentration-time curve,"Ritonavir caused a major pharmacokinetic interaction, increasing the area under the concentration-time curve of loperamide from 104 +/- 60 h x pmol/ml after placebo to 276 +/- 68 h.",Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719726/),h,276,38655,DB00836,Loperamide
,11719726,time to reach maximum concentration after drug administration [t(max)],"pmol/ml and delayed formation of the major metabolite desmethylloperamide (time to reach maximum concentration after drug administration [t(max)], 7.1 +/- 2.6 hours versus 19.6 +/- 9.1 hours).",Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719726/),h,7.1,38656,DB00836,Loperamide
,11719726,time to reach maximum concentration after drug administration [t(max)],"pmol/ml and delayed formation of the major metabolite desmethylloperamide (time to reach maximum concentration after drug administration [t(max)], 7.1 +/- 2.6 hours versus 19.6 +/- 9.1 hours).",Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719726/),h,19.6,38657,DB00836,Loperamide
,10424324,time to reach Cmax (tmax),"However, significant (P < 0.05) changes in the time to reach Cmax (tmax) values (median and range) were observed as, compared with administration of desmopressin alone (1.3 h and 0.5-4.0), it was longer after pretreatment with loperamide (2.0 h and 0.5-3.0) and shorter following pre-treatment with erythromycin (0.9 h and 0.5-1.3).",Changes in gastrointestinal motility influence the absorption of desmopressin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424324/),h,1.3,47854,DB00836,Loperamide
,10424324,time to reach Cmax (tmax),"However, significant (P < 0.05) changes in the time to reach Cmax (tmax) values (median and range) were observed as, compared with administration of desmopressin alone (1.3 h and 0.5-4.0), it was longer after pretreatment with loperamide (2.0 h and 0.5-3.0) and shorter following pre-treatment with erythromycin (0.9 h and 0.5-1.3).",Changes in gastrointestinal motility influence the absorption of desmopressin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424324/),,0.5-4.0,47855,DB00836,Loperamide
,10424324,time to reach Cmax (tmax),"However, significant (P < 0.05) changes in the time to reach Cmax (tmax) values (median and range) were observed as, compared with administration of desmopressin alone (1.3 h and 0.5-4.0), it was longer after pretreatment with loperamide (2.0 h and 0.5-3.0) and shorter following pre-treatment with erythromycin (0.9 h and 0.5-1.3).",Changes in gastrointestinal motility influence the absorption of desmopressin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424324/),h,2.0,47856,DB00836,Loperamide
,10424324,time to reach Cmax (tmax),"However, significant (P < 0.05) changes in the time to reach Cmax (tmax) values (median and range) were observed as, compared with administration of desmopressin alone (1.3 h and 0.5-4.0), it was longer after pretreatment with loperamide (2.0 h and 0.5-3.0) and shorter following pre-treatment with erythromycin (0.9 h and 0.5-1.3).",Changes in gastrointestinal motility influence the absorption of desmopressin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424324/),,0.5-3.0,47857,DB00836,Loperamide
,10424324,time to reach Cmax (tmax),"However, significant (P < 0.05) changes in the time to reach Cmax (tmax) values (median and range) were observed as, compared with administration of desmopressin alone (1.3 h and 0.5-4.0), it was longer after pretreatment with loperamide (2.0 h and 0.5-3.0) and shorter following pre-treatment with erythromycin (0.9 h and 0.5-1.3).",Changes in gastrointestinal motility influence the absorption of desmopressin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424324/),h,0.9,47858,DB00836,Loperamide
,10424324,time to reach Cmax (tmax),"However, significant (P < 0.05) changes in the time to reach Cmax (tmax) values (median and range) were observed as, compared with administration of desmopressin alone (1.3 h and 0.5-4.0), it was longer after pretreatment with loperamide (2.0 h and 0.5-3.0) and shorter following pre-treatment with erythromycin (0.9 h and 0.5-1.3).",Changes in gastrointestinal motility influence the absorption of desmopressin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424324/),,0.5-1.3,47859,DB00836,Loperamide
,15496339,retention times,"The retention times of loperamide hydrochloride and IS were 1.2 and 0.8 min, respectively.",LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496339/),min,1.2,51495,DB00836,Loperamide
,15496339,retention times,"The retention times of loperamide hydrochloride and IS were 1.2 and 0.8 min, respectively.",LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496339/),min,0.8,51496,DB00836,Loperamide
,15496339,area under the plasma concentration versus time curve from time 0 to 72 h (AUC72 h),The following pharmacokinetic parameters were elucidated after administering a single dose of four 2mg capsules of loperamide: the area under the plasma concentration versus time curve from time 0 to 72 h (AUC72 h) 19.26 +/- 7.79 ng h/ml; peak plasma concentration (Cmax) 1.18 +/- 0.37 ng/ml; time to Cmax (Tmax) 5.38 +/- 0.74 h; and elimination half-life (t1/2) 11.35 +/- 2.06 h.,LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496339/),[h·ng] / [ml],19.26,51497,DB00836,Loperamide
,15496339,peak plasma concentration (Cmax),The following pharmacokinetic parameters were elucidated after administering a single dose of four 2mg capsules of loperamide: the area under the plasma concentration versus time curve from time 0 to 72 h (AUC72 h) 19.26 +/- 7.79 ng h/ml; peak plasma concentration (Cmax) 1.18 +/- 0.37 ng/ml; time to Cmax (Tmax) 5.38 +/- 0.74 h; and elimination half-life (t1/2) 11.35 +/- 2.06 h.,LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496339/),[ng] / [ml],1.18,51498,DB00836,Loperamide
,15496339,time to Cmax (Tmax),The following pharmacokinetic parameters were elucidated after administering a single dose of four 2mg capsules of loperamide: the area under the plasma concentration versus time curve from time 0 to 72 h (AUC72 h) 19.26 +/- 7.79 ng h/ml; peak plasma concentration (Cmax) 1.18 +/- 0.37 ng/ml; time to Cmax (Tmax) 5.38 +/- 0.74 h; and elimination half-life (t1/2) 11.35 +/- 2.06 h.,LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496339/),h,5.38,51499,DB00836,Loperamide
,15496339,elimination half-life (t1/2),The following pharmacokinetic parameters were elucidated after administering a single dose of four 2mg capsules of loperamide: the area under the plasma concentration versus time curve from time 0 to 72 h (AUC72 h) 19.26 +/- 7.79 ng h/ml; peak plasma concentration (Cmax) 1.18 +/- 0.37 ng/ml; time to Cmax (Tmax) 5.38 +/- 0.74 h; and elimination half-life (t1/2) 11.35 +/- 2.06 h.,LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496339/),h,11.35,51500,DB00836,Loperamide
,30196106,objective response rate (ORR),"The objective response rate (ORR) in patients with heavily pretreated breast and upper GI cancers was 16.0% (4 PRs) and 8.3% (1CR, 1PR), respectively.","An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30196106/),%,16.0,57391,DB00836,Loperamide
,30196106,objective response rate (ORR),"The objective response rate (ORR) in patients with heavily pretreated breast and upper GI cancers was 16.0% (4 PRs) and 8.3% (1CR, 1PR), respectively.","An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30196106/),%,8.3,57392,DB00836,Loperamide
,25444541,constant flow rate,"Adequate chromatographic separation for analytes from plasma and saliva matrices was achieved using ACE C18 (50mm×2.1mm, 5μm) column, eluted by water/methanol/formic acid (30:70:0.1%, v/v), delivered isocratically at constant flow rate of 0.75ml/min.",Determination of loperamide in human plasma and saliva by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25444541/),[ml] / [min],0.75,66888,DB00836,Loperamide
,535599,half-life,"Following oral administration of [14C]loperamide hydrochloride in 1 mg/kg to rats, plasma levels of radioactivity reached maximum at 4 hrs and decreased with a half-life of 4.1 hrs.",Disposition and metabolism of [14C]loperamide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/535599/),h,4.1,71918,DB00836,Loperamide
,15530130,area under the concentration-time curve from zero to infinity,"Saquinavir exposure was reduced by 54% when given with loperamide (median area under the concentration-time curve from zero to infinity [range], 1189 [243-2113] vs 550 [234-1468] pmol . h/mL; p = 0.016) with unchanged renal clearance.",Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15530130/),[h·pM] / [ml],1189,75295,DB00836,Loperamide
,15530130,area under the concentration-time curve from zero to infinity,"Saquinavir exposure was reduced by 54% when given with loperamide (median area under the concentration-time curve from zero to infinity [range], 1189 [243-2113] vs 550 [234-1468] pmol . h/mL; p = 0.016) with unchanged renal clearance.",Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15530130/),[h·pM] / [ml],550,75296,DB00836,Loperamide
,15530130,metabolic clearance,"In contrast, loperamide concentrations increased and desmethylloperamide concentrations decreased during saquinavir coadministration, resulting in a reduced metabolic clearance of loperamide (median [range], 544 [224-1393] vs 443 [238-692] mL/min; p = 0.016).",Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15530130/),[ml] / [min],544,75297,DB00836,Loperamide
,15530130,metabolic clearance,"In contrast, loperamide concentrations increased and desmethylloperamide concentrations decreased during saquinavir coadministration, resulting in a reduced metabolic clearance of loperamide (median [range], 544 [224-1393] vs 443 [238-692] mL/min; p = 0.016).",Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15530130/),[ml] / [min],443,75298,DB00836,Loperamide
,7799022,recovery time,"Dose-dependent, reversible, noncumulative granulocytopenia was the dose-limiting toxicity (nadir, days 6 to 9; median recovery time, 5 days).",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),d,5,83116,DB00836,Loperamide
,7799022,terminal half-life,"CPT-11 plasma disposition was bi- or triphasic, with a mean terminal half-life of 14.2 +/- 0.9 hours (mean +/- SEM).",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),h,14.2,83117,DB00836,Loperamide
,7799022,volume of distribution (Vdss),"The mean volume of distribution (Vdss) was 157 +/- 8 L/m2, and total-body clearance was 15 +/- 1 L/m2/h.",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),[l] / [m2],157,83118,DB00836,Loperamide
,7799022,total-body clearance,"The mean volume of distribution (Vdss) was 157 +/- 8 L/m2, and total-body clearance was 15 +/- 1 L/m2/h.",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),[l] / [h·m2],15,83119,DB00836,Loperamide
,7799022,apparent half-life,SN-38 plasma decay had an apparent half-life of 13.8 +/- 1.4 hours.,Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),h,13.8,83120,DB00836,Loperamide
,7799022,MTD,"The MTD of CPT-11 administered as a 30-minute IV infusion every 3 weeks is 600 mg/m2, with granulocytopenia being dose-limiting.",Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799022/),,600,83121,DB00836,Loperamide
,27708583,encapsulation efficiencies,"The average encapsulation efficiencies were 87 ± 3.78% w/w and 84 ± 5.17%, accordingly.",Preparation and Characterization of Loperamide-Loaded Dynasan 114 Solid Lipid Nanoparticles for Increased Oral Absorption In the Treatment of Diarrhea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27708583/),[%·w] / [w],87,85251,DB00836,Loperamide
,27708583,encapsulation efficiencies,"The average encapsulation efficiencies were 87 ± 3.78% w/w and 84 ± 5.17%, accordingly.",Preparation and Characterization of Loperamide-Loaded Dynasan 114 Solid Lipid Nanoparticles for Increased Oral Absorption In the Treatment of Diarrhea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27708583/),%,84,85252,DB00836,Loperamide
,27708583,relative bioavailabilities,"The relative bioavailabilities of LPM-SLNs were 227 and 153%, respectively, as compared that of the LPM tablet.",Preparation and Characterization of Loperamide-Loaded Dynasan 114 Solid Lipid Nanoparticles for Increased Oral Absorption In the Treatment of Diarrhea. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27708583/),%,227,85253,DB00836,Loperamide
,27708583,relative bioavailabilities,"The relative bioavailabilities of LPM-SLNs were 227 and 153%, respectively, as compared that of the LPM tablet.",Preparation and Characterization of Loperamide-Loaded Dynasan 114 Solid Lipid Nanoparticles for Increased Oral Absorption In the Treatment of Diarrhea. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27708583/),%,153,85254,DB00836,Loperamide
,438356,biologic half-life,"The mean biologic half-life, calculated from the elimination phase of the log serum concentration-versus-time data, was 10.8 +/- 0.6 hours for the overall study, 10.2 +/- 0.6 hours for the syrup formulation, and 11.2 +/- 0.8 hours for the capsules.",Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/438356/),h,10.8,87638,DB00836,Loperamide
,438356,biologic half-life,"The mean biologic half-life, calculated from the elimination phase of the log serum concentration-versus-time data, was 10.8 +/- 0.6 hours for the overall study, 10.2 +/- 0.6 hours for the syrup formulation, and 11.2 +/- 0.8 hours for the capsules.",Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/438356/),h,10.2,87639,DB00836,Loperamide
,438356,biologic half-life,"The mean biologic half-life, calculated from the elimination phase of the log serum concentration-versus-time data, was 10.8 +/- 0.6 hours for the overall study, 10.2 +/- 0.6 hours for the syrup formulation, and 11.2 +/- 0.8 hours for the capsules.",Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/438356/),h,11.2,87640,DB00836,Loperamide
,438356,mean time,"The loperamide from the syrup was absorbed more rapidly than from the capsule formulation, with the peak serum levels observed at a mean time of 2.4 +/- 0.7 hours for the syrup and 5.2 +/- 0.3 hours for the capsule formulation.",Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/438356/),h,2.4,87641,DB00836,Loperamide
,438356,mean time,"The loperamide from the syrup was absorbed more rapidly than from the capsule formulation, with the peak serum levels observed at a mean time of 2.4 +/- 0.7 hours for the syrup and 5.2 +/- 0.3 hours for the capsule formulation.",Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/438356/),h,5.2,87642,DB00836,Loperamide
,438356,Excretion,Excretion of approximately 1 per cent of the dose in the urine as unchanged loperamide after seven days was observed independent of the particular dosage form that was administered.,Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/438356/),%,1,87643,DB00836,Loperamide
,8622015,response duration,"The median response duration was 8.1 months (range, 4.0 to 16.0) and the median survival time was 12.1 months (range, 2.1 to 21.7) for all 41 patients.",Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622015/),month,8.1,100300,DB00836,Loperamide
,8622015,survival time,"The median response duration was 8.1 months (range, 4.0 to 16.0) and the median survival time was 12.1 months (range, 2.1 to 21.7) for all 41 patients.",Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622015/),month,12.1,100301,DB00836,Loperamide
,31170630,constant flow-rate,"Chromatographic resolution of both analytes (BM and HBM) and the I.S. (loperamide) was achieved on an Atlantis dC18 column using 0.2% formic acid:acetonitrile (25:75, v/v) as an eluant delivered at a constant flow-rate of 0.5 mL/min.",Simultaneous determination of bendamustine and γ-hydroxybendamustine in mice dried blood spots and its application in a mice pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31170630/),[ml] / [min],0.5,100730,DB00836,Loperamide
,31170630,total chromatographic run time,The total chromatographic run time was 3.2 min.,Simultaneous determination of bendamustine and γ-hydroxybendamustine in mice dried blood spots and its application in a mice pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31170630/),min,3.2,100731,DB00836,Loperamide
,31170630,m,"The MS/MS ion transitions monitored were m/z 358.0 → 228.0, 374.0 → 338.0 and 477.0 → 210.0 for BM, HBM and the I.S, respectively.",Simultaneous determination of bendamustine and γ-hydroxybendamustine in mice dried blood spots and its application in a mice pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31170630/),,358.0,100732,DB00836,Loperamide
,16003560,mass ratio,"Pharmacokinetic results revealed a mass ratio of plasma SN-38G/SN-38, which was very similar to historical controls (7.15 +/- 5.67, n = 18).","A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003560/),,7.15,106007,DB00836,Loperamide
,16758263,elimination half-life (t(1/2)),"Itraconazole raised the peak plasma loperamide concentration (Cmax) 2.9-fold (range, 1.2-5.0; P < 0.001) and the total area under the plasma loperamide concentration-time curve (AUC(0-infinity)) 3.8-fold (1.4-6.6; P < 0.001) and prolonged the elimination half-life (t(1/2)) of loperamide from 11.9 to 18.7 h (P < 0.001).","Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,11.,108340,DB00836,Loperamide
,16758263,elimination half-life (t(1/2)),"Itraconazole raised the peak plasma loperamide concentration (Cmax) 2.9-fold (range, 1.2-5.0; P < 0.001) and the total area under the plasma loperamide concentration-time curve (AUC(0-infinity)) 3.8-fold (1.4-6.6; P < 0.001) and prolonged the elimination half-life (t(1/2)) of loperamide from 11.9 to 18.7 h (P < 0.001).","Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,18,108341,DB00836,Loperamide
,16758263,t(1/2),Gemfibrozil raised the Cmax of loperamide 1.6-fold (0.9-3.2; P < 0.05) and its AUC(0-infinity) 2.2-fold (1.0-3.7; P < 0.05) and prolonged its t(1/2) to 16.7 h (P < 0.01).,"Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,16.7,108342,DB00836,Loperamide
,16758263,t(1/2),The combination of itraconazole and gemfibrozil raised the Cmax of loperamide 4.2-fold (1.5-8.7; P < 0.001) and its AUC(0-infinity) 12.6-fold (4.3-21.8; P < 0.001) and prolonged the t(1/2) of loperamide to 36.9 h (P < 0.001).,"Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,36.9,108343,DB00836,Loperamide
,14586389,peak plasma drug concentration,"We found no significant difference in loperamide pharmacokinetics between individuals homozygous for the C and the T alleles in position 3435 of MDR1, as follows: peak plasma drug concentration, 3164 +/- 1053 pg/mL and 3021 +/- 984 pg/mL; area under the concentration-time curve from 0 to 8 hours, 14414 +/- 4756 pg. h/mL and 14923 +/- 6466 pg. h/mL; and time to peak plasma drug concentration, 3.9 +/- 1.4 hours and 3.9 +/- 2.6 hours for the MDR1 3435CC and 3435TT genotypes, respectively (P >.05, for all parameters).",No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586389/),[pg] / [ml],3164,115140,DB00836,Loperamide
,14586389,peak plasma drug concentration,"We found no significant difference in loperamide pharmacokinetics between individuals homozygous for the C and the T alleles in position 3435 of MDR1, as follows: peak plasma drug concentration, 3164 +/- 1053 pg/mL and 3021 +/- 984 pg/mL; area under the concentration-time curve from 0 to 8 hours, 14414 +/- 4756 pg. h/mL and 14923 +/- 6466 pg. h/mL; and time to peak plasma drug concentration, 3.9 +/- 1.4 hours and 3.9 +/- 2.6 hours for the MDR1 3435CC and 3435TT genotypes, respectively (P >.05, for all parameters).",No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586389/),[pg] / [ml],3021,115141,DB00836,Loperamide
,14586389,area under the concentration-time curve from 0 to 8 hours,"We found no significant difference in loperamide pharmacokinetics between individuals homozygous for the C and the T alleles in position 3435 of MDR1, as follows: peak plasma drug concentration, 3164 +/- 1053 pg/mL and 3021 +/- 984 pg/mL; area under the concentration-time curve from 0 to 8 hours, 14414 +/- 4756 pg. h/mL and 14923 +/- 6466 pg. h/mL; and time to peak plasma drug concentration, 3.9 +/- 1.4 hours and 3.9 +/- 2.6 hours for the MDR1 3435CC and 3435TT genotypes, respectively (P >.05, for all parameters).",No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586389/),[h·pg] / [ml],14414,115142,DB00836,Loperamide
,14586389,area under the concentration-time curve from 0 to 8 hours,"We found no significant difference in loperamide pharmacokinetics between individuals homozygous for the C and the T alleles in position 3435 of MDR1, as follows: peak plasma drug concentration, 3164 +/- 1053 pg/mL and 3021 +/- 984 pg/mL; area under the concentration-time curve from 0 to 8 hours, 14414 +/- 4756 pg. h/mL and 14923 +/- 6466 pg. h/mL; and time to peak plasma drug concentration, 3.9 +/- 1.4 hours and 3.9 +/- 2.6 hours for the MDR1 3435CC and 3435TT genotypes, respectively (P >.05, for all parameters).",No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586389/),[h·pg] / [ml],14923,115143,DB00836,Loperamide
,14586389,time to peak plasma drug concentration,"We found no significant difference in loperamide pharmacokinetics between individuals homozygous for the C and the T alleles in position 3435 of MDR1, as follows: peak plasma drug concentration, 3164 +/- 1053 pg/mL and 3021 +/- 984 pg/mL; area under the concentration-time curve from 0 to 8 hours, 14414 +/- 4756 pg. h/mL and 14923 +/- 6466 pg. h/mL; and time to peak plasma drug concentration, 3.9 +/- 1.4 hours and 3.9 +/- 2.6 hours for the MDR1 3435CC and 3435TT genotypes, respectively (P >.05, for all parameters).",No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586389/),h,3.9,115144,DB00836,Loperamide
,14586389,time to peak plasma drug concentration,"We found no significant difference in loperamide pharmacokinetics between individuals homozygous for the C and the T alleles in position 3435 of MDR1, as follows: peak plasma drug concentration, 3164 +/- 1053 pg/mL and 3021 +/- 984 pg/mL; area under the concentration-time curve from 0 to 8 hours, 14414 +/- 4756 pg. h/mL and 14923 +/- 6466 pg. h/mL; and time to peak plasma drug concentration, 3.9 +/- 1.4 hours and 3.9 +/- 2.6 hours for the MDR1 3435CC and 3435TT genotypes, respectively (P >.05, for all parameters).",No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586389/),h,3.9,115145,DB00836,Loperamide
,33148479,PFS,"The median PFS was 9.1 months for A+T versus 7.4 months for A-200 (hazard ratio, 0.815; 95% confidence interval, 0.556-1.193; P = .293).",nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33148479/),month,9.1,130282,DB00836,Loperamide
,33148479,PFS,"The median PFS was 9.1 months for A+T versus 7.4 months for A-200 (hazard ratio, 0.815; 95% confidence interval, 0.556-1.193; P = .293).",nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33148479/),month,7.4,130283,DB00836,Loperamide
,31512028,tmax,A median tmax of ~ 6 h was observed for neratinib during both periods.,Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),h,6,137527,DB00836,Loperamide
,31512028,CLss/F,"Apparent clearance and volume of distribution were similar for Periods 1 and 2: mean CLss/F 308.2 and 322.1 L/h; mean Vzτ/F 7995 and 10,318 L, respectively.",Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),[l] / [h],308.2,137528,DB00836,Loperamide
,31512028,CLss/F,"Apparent clearance and volume of distribution were similar for Periods 1 and 2: mean CLss/F 308.2 and 322.1 L/h; mean Vzτ/F 7995 and 10,318 L, respectively.",Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),[l] / [h],322.1,137529,DB00836,Loperamide
,31512028,Vzτ/F,"Apparent clearance and volume of distribution were similar for Periods 1 and 2: mean CLss/F 308.2 and 322.1 L/h; mean Vzτ/F 7995 and 10,318 L, respectively.",Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),l,7995,137530,DB00836,Loperamide
,31512028,Vzτ/F,"Apparent clearance and volume of distribution were similar for Periods 1 and 2: mean CLss/F 308.2 and 322.1 L/h; mean Vzτ/F 7995 and 10,318 L, respectively.",Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),l,"10,318",137531,DB00836,Loperamide
,31512028,half-life,The half-life of neratinib increased in the presence of loperamide from 18.0 to 22.2 h.,Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),h,18.0,137532,DB00836,Loperamide
,31512028,half-life,The half-life of neratinib increased in the presence of loperamide from 18.0 to 22.2 h.,Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),h,22.2,137533,DB00836,Loperamide
,31512028,Cmax,"Mean exposure was within the same range without and with loperamide administration: Cmax 61.2 ng/mL and 49.5 ng/mL; AUClast 1086 ng h/mL and 1153 ng h/mL, and AUCtau 779 ng h/mL and 745 ng h/mL, respectively.",Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),[ng] / [ml],61.2,137534,DB00836,Loperamide
,31512028,Cmax,"Mean exposure was within the same range without and with loperamide administration: Cmax 61.2 ng/mL and 49.5 ng/mL; AUClast 1086 ng h/mL and 1153 ng h/mL, and AUCtau 779 ng h/mL and 745 ng h/mL, respectively.",Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),[ng] / [ml],49.5,137535,DB00836,Loperamide
,31512028,AUClast,"Mean exposure was within the same range without and with loperamide administration: Cmax 61.2 ng/mL and 49.5 ng/mL; AUClast 1086 ng h/mL and 1153 ng h/mL, and AUCtau 779 ng h/mL and 745 ng h/mL, respectively.",Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),[h·ng] / [ml],1086,137536,DB00836,Loperamide
,31512028,AUClast,"Mean exposure was within the same range without and with loperamide administration: Cmax 61.2 ng/mL and 49.5 ng/mL; AUClast 1086 ng h/mL and 1153 ng h/mL, and AUCtau 779 ng h/mL and 745 ng h/mL, respectively.",Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),[h·ng] / [ml],1153,137537,DB00836,Loperamide
,31512028,AUCtau,"Mean exposure was within the same range without and with loperamide administration: Cmax 61.2 ng/mL and 49.5 ng/mL; AUClast 1086 ng h/mL and 1153 ng h/mL, and AUCtau 779 ng h/mL and 745 ng h/mL, respectively.",Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),[h·ng] / [ml],779,137538,DB00836,Loperamide
,31512028,AUCtau,"Mean exposure was within the same range without and with loperamide administration: Cmax 61.2 ng/mL and 49.5 ng/mL; AUClast 1086 ng h/mL and 1153 ng h/mL, and AUCtau 779 ng h/mL and 745 ng h/mL, respectively.",Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31512028/),[h·ng] / [ml],745,137539,DB00836,Loperamide
,14988754,terminal half-life,"The pharmacokinetics of irinotecan are characterized by a 2- or 3-compartment decay, with a terminal half-life of about 10 h, a total volume of distribution of 150 l/m(2) and a total plasma clearance of 15 l/h/m(2).",Pharmacology of irinotecan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14988754/),h,10,138344,DB00836,Loperamide
,14988754,total volume of distribution,"The pharmacokinetics of irinotecan are characterized by a 2- or 3-compartment decay, with a terminal half-life of about 10 h, a total volume of distribution of 150 l/m(2) and a total plasma clearance of 15 l/h/m(2).",Pharmacology of irinotecan. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14988754/),[l] / [m(2],150,138345,DB00836,Loperamide
,14988754,total plasma clearance,"The pharmacokinetics of irinotecan are characterized by a 2- or 3-compartment decay, with a terminal half-life of about 10 h, a total volume of distribution of 150 l/m(2) and a total plasma clearance of 15 l/h/m(2).",Pharmacology of irinotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14988754/),[h·l] / [m(2],15,138346,DB00836,Loperamide
,14988754,half-life,SN-38 AUC is only a small fraction of that of irinotecan (2-4%) and SN-38 is eliminated from plasma with a half-life of about 12 h.,Pharmacology of irinotecan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14988754/),h,12,138347,DB00836,Loperamide
,25400284,flow rate,"Chromatographic separation was performed on a Thermo Scientific Accucore C18 column with an isocratic mobile phase composed of 0.1% v/v formic acid in purified water-methanol (20:80, v/v), at a flow rate of 0.3 mL/min.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[ml] / [min],0.3,138803,DB00836,Loperamide
,25400284,AUC0-t,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[h·ng] / [ml],2285.79,138804,DB00836,Loperamide
,25400284,Cmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[ng] / [ml],726.10,138805,DB00836,Loperamide
,25400284,Cmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[h·ng] / [ml],2363.25,138806,DB00836,Loperamide
,25400284,Cmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[ng] / [ml],713.91,138807,DB00836,Loperamide
,25400284,Tmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),h,0.94,138808,DB00836,Loperamide
,25400284,Tmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),h,0.83,138809,DB00836,Loperamide
down to,31389695,IC50,"We previously identified, by high-throughput screening, 4,8-dimethylcoumarin inhibitors of murine slc26a3 with IC50 down to ∼150 nM.","4,8-Dimethylcoumarin Inhibitors of Intestinal Anion Exchanger slc26a3 (Downregulated in Adenoma) for Anti-Absorptive Therapy of Constipation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31389695/),nM,∼150,138909,DB00836,Loperamide
,31389695,IC50,"The most potent inhibitors were produced by replacements at C7, including 3-iodo- (4az) and 3-trifluoromethyl- (4be), with IC50 of 40 and 25 nM, respectively.","4,8-Dimethylcoumarin Inhibitors of Intestinal Anion Exchanger slc26a3 (Downregulated in Adenoma) for Anti-Absorptive Therapy of Constipation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31389695/),nM,40,138910,DB00836,Loperamide
,31389695,IC50,"The most potent inhibitors were produced by replacements at C7, including 3-iodo- (4az) and 3-trifluoromethyl- (4be), with IC50 of 40 and 25 nM, respectively.","4,8-Dimethylcoumarin Inhibitors of Intestinal Anion Exchanger slc26a3 (Downregulated in Adenoma) for Anti-Absorptive Therapy of Constipation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31389695/),nM,25,138911,DB00836,Loperamide
,8838438,Cmax,"2. Coadministration of cotrimoxazole with loperamide oxide did not alter the tmax, Cmax and AUC of loperamide oxide, whereas the Cmax (0.32 +/- 0.14 ng ml-1 without cotrimoxazole; 0.45 +/- 0.18 ng ml-1 with cotrimoxazole; P < 0.05) and AUC (8.13 +/- 1.91 ng ml-1 h without cotrimoxazole; 12.50 +/- 4.60 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide were significantly increased.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[ng] / [ml],0.32,144023,DB00836,Loperamide
,8838438,Cmax,"2. Coadministration of cotrimoxazole with loperamide oxide did not alter the tmax, Cmax and AUC of loperamide oxide, whereas the Cmax (0.32 +/- 0.14 ng ml-1 without cotrimoxazole; 0.45 +/- 0.18 ng ml-1 with cotrimoxazole; P < 0.05) and AUC (8.13 +/- 1.91 ng ml-1 h without cotrimoxazole; 12.50 +/- 4.60 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide were significantly increased.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[ng] / [ml],0.45,144024,DB00836,Loperamide
,8838438,AUC,"2. Coadministration of cotrimoxazole with loperamide oxide did not alter the tmax, Cmax and AUC of loperamide oxide, whereas the Cmax (0.32 +/- 0.14 ng ml-1 without cotrimoxazole; 0.45 +/- 0.18 ng ml-1 with cotrimoxazole; P < 0.05) and AUC (8.13 +/- 1.91 ng ml-1 h without cotrimoxazole; 12.50 +/- 4.60 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide were significantly increased.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[h·ng] / [ml],8.13,144025,DB00836,Loperamide
,8838438,AUC,"2. Coadministration of cotrimoxazole with loperamide oxide did not alter the tmax, Cmax and AUC of loperamide oxide, whereas the Cmax (0.32 +/- 0.14 ng ml-1 without cotrimoxazole; 0.45 +/- 0.18 ng ml-1 with cotrimoxazole; P < 0.05) and AUC (8.13 +/- 1.91 ng ml-1 h without cotrimoxazole; 12.50 +/- 4.60 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide were significantly increased.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[h·ng] / [ml],12.50,144026,DB00836,Loperamide
,8838438,Cmax,"3. Coadministration of cotrimoxazole with loperamide significantly increased the Cmax (0.74 +/- 0.22 ng ml-1 without cotrimoxazole; 1.49 +/- 0.81 ng ml-1 with cotrimoxazole; P < 0.01) and AUC (13.40 +/- 3.80 ng ml-1 h without cotrimoxazole; 25.30 +/- 11.10 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide, whilst its tmax and t1/2,z were not significantly altered.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[ng] / [ml],0.74,144027,DB00836,Loperamide
,8838438,Cmax,"3. Coadministration of cotrimoxazole with loperamide significantly increased the Cmax (0.74 +/- 0.22 ng ml-1 without cotrimoxazole; 1.49 +/- 0.81 ng ml-1 with cotrimoxazole; P < 0.01) and AUC (13.40 +/- 3.80 ng ml-1 h without cotrimoxazole; 25.30 +/- 11.10 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide, whilst its tmax and t1/2,z were not significantly altered.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[ng] / [ml],1.49,144028,DB00836,Loperamide
,8838438,AUC,"3. Coadministration of cotrimoxazole with loperamide significantly increased the Cmax (0.74 +/- 0.22 ng ml-1 without cotrimoxazole; 1.49 +/- 0.81 ng ml-1 with cotrimoxazole; P < 0.01) and AUC (13.40 +/- 3.80 ng ml-1 h without cotrimoxazole; 25.30 +/- 11.10 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide, whilst its tmax and t1/2,z were not significantly altered.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[h·ng] / [ml],13.40,144029,DB00836,Loperamide
,8838438,AUC,"3. Coadministration of cotrimoxazole with loperamide significantly increased the Cmax (0.74 +/- 0.22 ng ml-1 without cotrimoxazole; 1.49 +/- 0.81 ng ml-1 with cotrimoxazole; P < 0.01) and AUC (13.40 +/- 3.80 ng ml-1 h without cotrimoxazole; 25.30 +/- 11.10 ng ml-1 h with cotrimoxazole; P < 0.005) of loperamide, whilst its tmax and t1/2,z were not significantly altered.",Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838438/),[h·ng] / [ml],25.30,144030,DB00836,Loperamide
,9229329,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 115 mg/m2 in the daily schedule and 145 mg/m2 in the weekly schedule.,CPT-11: the European clinical development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229329/),[mg] / [m2],115,154289,DB00836,Loperamide
,9229329,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 115 mg/m2 in the daily schedule and 145 mg/m2 in the weekly schedule.,CPT-11: the European clinical development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229329/),[mg] / [m2],145,154290,DB00836,Loperamide
,12000531,T(1/2app),"The appearance of MXD in faeces was significantly delayed after the i.v. and s.c. coadministrations of MXD with LPM (T(1/2app)=5.87 and 10.6 h, respectively) than that observed after the treatment with MXD alone (T(1/2app)=3.48 and 5.12 h).",Loperamide-induced enhancement of moxidectin availability in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000531/),h,5.87,180499,DB00836,Loperamide
,12000531,T(1/2app),"The appearance of MXD in faeces was significantly delayed after the i.v. and s.c. coadministrations of MXD with LPM (T(1/2app)=5.87 and 10.6 h, respectively) than that observed after the treatment with MXD alone (T(1/2app)=3.48 and 5.12 h).",Loperamide-induced enhancement of moxidectin availability in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000531/),h,10.6,180500,DB00836,Loperamide
,12000531,T(1/2app),"The appearance of MXD in faeces was significantly delayed after the i.v. and s.c. coadministrations of MXD with LPM (T(1/2app)=5.87 and 10.6 h, respectively) than that observed after the treatment with MXD alone (T(1/2app)=3.48 and 5.12 h).",Loperamide-induced enhancement of moxidectin availability in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000531/),h,3.48,180501,DB00836,Loperamide
,12000531,T(1/2app),"The appearance of MXD in faeces was significantly delayed after the i.v. and s.c. coadministrations of MXD with LPM (T(1/2app)=5.87 and 10.6 h, respectively) than that observed after the treatment with MXD alone (T(1/2app)=3.48 and 5.12 h).",Loperamide-induced enhancement of moxidectin availability in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000531/),h,5.12,180502,DB00836,Loperamide
,8112368,Cmax,The mean Cmax values were significantly greater for the didanosine single agent (2.04 micrograms.,Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112368/),μg,2.04,186193,DB00836,Loperamide
,8112368,t1/2,"The t1/2 in males was significantly greater than in females for the didanosine (1.75 vs 1.12 h, respectively) and didanosine with metoclopramide treatments (1.74 vs 1.20 h, respectively).",Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112368/),h,1.75,186194,DB00836,Loperamide
,8112368,t1/2,"The t1/2 in males was significantly greater than in females for the didanosine (1.75 vs 1.12 h, respectively) and didanosine with metoclopramide treatments (1.74 vs 1.20 h, respectively).",Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112368/),h,1.12,186195,DB00836,Loperamide
,8112368,t1/2,"The t1/2 in males was significantly greater than in females for the didanosine (1.75 vs 1.12 h, respectively) and didanosine with metoclopramide treatments (1.74 vs 1.20 h, respectively).",Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112368/),h,1.74,186196,DB00836,Loperamide
,8112368,t1/2,"The t1/2 in males was significantly greater than in females for the didanosine (1.75 vs 1.12 h, respectively) and didanosine with metoclopramide treatments (1.74 vs 1.20 h, respectively).",Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive asymptomatic male and female patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112368/),h,1.20,186197,DB00836,Loperamide
,14769140,AUC,"At the 750-mg/m(2) dose, the AUC for CPT-11 (21.6 microg x h/ml) matched the AUC (21.6 microg x h/ml) in the non-EIAED group treated with 350 mg/m(2) of CPT-11.",Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14769140/),[h·μg] / [ml],21.6,189632,DB00836,Loperamide
,8556221,AUC0 infinity,"The following mean values were obtained after intake of 16 mg loperamide as film coated tablets: AUC0 infinity 62.04 ngh/ml, Cmax 3.35 ng/ml, tmax 4.08 h, t1/2 19.66 h and after administration of the capsules: AUC0 infinity 66.56 ngh/ml, Cmax 3.98 ng/ml, tmax 4.38 h, t1/2 18.43 h.",Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556221/),[ngh] / [ml],62.04,203552,DB00836,Loperamide
,8556221,Cmax,"The following mean values were obtained after intake of 16 mg loperamide as film coated tablets: AUC0 infinity 62.04 ngh/ml, Cmax 3.35 ng/ml, tmax 4.08 h, t1/2 19.66 h and after administration of the capsules: AUC0 infinity 66.56 ngh/ml, Cmax 3.98 ng/ml, tmax 4.38 h, t1/2 18.43 h.",Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556221/),[ng] / [ml],3.35,203553,DB00836,Loperamide
,8556221,tmax,"The following mean values were obtained after intake of 16 mg loperamide as film coated tablets: AUC0 infinity 62.04 ngh/ml, Cmax 3.35 ng/ml, tmax 4.08 h, t1/2 19.66 h and after administration of the capsules: AUC0 infinity 66.56 ngh/ml, Cmax 3.98 ng/ml, tmax 4.38 h, t1/2 18.43 h.",Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556221/),h,4.08,203554,DB00836,Loperamide
,8556221,t1/2,"The following mean values were obtained after intake of 16 mg loperamide as film coated tablets: AUC0 infinity 62.04 ngh/ml, Cmax 3.35 ng/ml, tmax 4.08 h, t1/2 19.66 h and after administration of the capsules: AUC0 infinity 66.56 ngh/ml, Cmax 3.98 ng/ml, tmax 4.38 h, t1/2 18.43 h.",Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556221/),h,19.66,203555,DB00836,Loperamide
,8556221,AUC0 infinity,"The following mean values were obtained after intake of 16 mg loperamide as film coated tablets: AUC0 infinity 62.04 ngh/ml, Cmax 3.35 ng/ml, tmax 4.08 h, t1/2 19.66 h and after administration of the capsules: AUC0 infinity 66.56 ngh/ml, Cmax 3.98 ng/ml, tmax 4.38 h, t1/2 18.43 h.",Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556221/),[ngh] / [ml],66.56,203556,DB00836,Loperamide
,8556221,Cmax,"The following mean values were obtained after intake of 16 mg loperamide as film coated tablets: AUC0 infinity 62.04 ngh/ml, Cmax 3.35 ng/ml, tmax 4.08 h, t1/2 19.66 h and after administration of the capsules: AUC0 infinity 66.56 ngh/ml, Cmax 3.98 ng/ml, tmax 4.38 h, t1/2 18.43 h.",Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556221/),[ng] / [ml],3.98,203557,DB00836,Loperamide
,8556221,tmax,"The following mean values were obtained after intake of 16 mg loperamide as film coated tablets: AUC0 infinity 62.04 ngh/ml, Cmax 3.35 ng/ml, tmax 4.08 h, t1/2 19.66 h and after administration of the capsules: AUC0 infinity 66.56 ngh/ml, Cmax 3.98 ng/ml, tmax 4.38 h, t1/2 18.43 h.",Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556221/),h,4.38,203558,DB00836,Loperamide
,8556221,t1/2,"The following mean values were obtained after intake of 16 mg loperamide as film coated tablets: AUC0 infinity 62.04 ngh/ml, Cmax 3.35 ng/ml, tmax 4.08 h, t1/2 19.66 h and after administration of the capsules: AUC0 infinity 66.56 ngh/ml, Cmax 3.98 ng/ml, tmax 4.38 h, t1/2 18.43 h.",Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556221/),h,18.43,203559,DB00836,Loperamide
,10993521,extraction efficiency,"The extraction efficiency of LOP and DMLOP from human plasma was 72.3+/-1.50% (range: 70.7-73.7%) and 79.4+/-12.8% (64.9-88.8%), respectively.",Quantitation of loperamide and N-demethyl-loperamide in human plasma using electrospray ionization with selected reaction ion monitoring liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993521/),%,72.3,232960,DB00836,Loperamide
,10993521,extraction efficiency,"The extraction efficiency of LOP and DMLOP from human plasma was 72.3+/-1.50% (range: 70.7-73.7%) and 79.4+/-12.8% (64.9-88.8%), respectively.",Quantitation of loperamide and N-demethyl-loperamide in human plasma using electrospray ionization with selected reaction ion monitoring liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993521/),%,79.4,232961,DB00836,Loperamide
,9915332,elimination half life,Drug activity in the tissue revealed an elimination half life of 2.3 h and negligible concentration in the blood.,Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist--loperamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915332/),h,2.3,251568,DB00836,Loperamide
